Alcohol Use Disorder (AUD)Substance Use Disorders (SUD)Psilocybin

Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice

This mice study found that psilocybin reduced alcohol consumption for three days, but this effect was only present in male mice.

Authors

  • Alper, K.
  • Cange, J.
  • Sah, R.

Published

Frontiers in Pharmacology
individual Study

Abstract

The classical psychedelic psilocybin is of interest as a treatment for alcohol use disorder (AUD). This study investigated the effects of psilocybin on voluntary ethanol consumption in adult male and female C57BL/6J mice administered saline or psilocybin intraperitoneally as a single dose of 0.1, 0.5, 1.0 or 2.0 mg/kg and provided 20% ethanol utilizing a two-bottle choice alcohol drinking paradigm. Ethanol was provided continuously for 3 days immediately following the administration of psilocybin, then withheld for 2 days, and then provided continuously for two subsequent additional days. A multilevel model (MLM) for repeated measures was used to compare ethanol consumption and preference in psilocybin-treated groups versus controls. Ethanol consumption and preference were reduced in male mice during the 3-day interval that immediately followed psilocybin administration. The effect of psilocybin on ethanol consumption was dose-related and was consistent across the 3-day interval at dosages of 0.5 mg/kg or greater. Psilocybin had no effect on consumption or preference when ethanol was subsequently reintroduced after 2 days of withdrawal. In contrast to males, psilocybin had no significant effect on ethanol consumption or preference in female mice at any dosage or time point. The lack of an effect of psilocybin on quinine preference, and its limited interaction with locomotor activity indicated that the observed reduction in voluntary ethanol consumption was not attributable to altered taste perception or motor effects. Total fluid consumption was increased in males at some time points and psilocybin dosages and unchanged in females, and the absence of any decrease in either group at any time point indicated that the observed reduction in ethanol consumption was not mediated by nonspecific effects on consummatory behavior. The finding of a sex-dependent effect of psilocybin on ethanol consumption suggests that the C57BL/6J mouse may provide a useful experimental approach to modeling sex differences in vulnerability to AUD in addition to investigation of the neurobiological basis of the effect of classical psychedelics on alcohol drinking behavior.

Available with Blossom Pro

Research Summary of 'Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice'

Introduction

Classical psychedelics, particularly LSD and psilocybin, have been associated with prolonged reductions in alcohol use in observational and controlled clinical studies, and there is growing interest in their therapeutic potential for alcohol use disorder (AUD). The authors note that preclinical animal models can aid target identification and mechanistic investigation; prior rodent studies of psychedelics or 5-HT2A receptor (5-HT2AR) agonist analogs have reported reduced ethanol consumption or preference in at least one experimental condition, with dose-related effects in some cases. The clinical literature shows persistent decreases in drinking that outlast the drugs' metabolic half-lives, motivating preclinical work to probe duration, dose-dependence and mechanisms. Alper and colleagues set out to evaluate the effect of a single intraperitoneal dose of psilocybin on voluntary ethanol consumption and preference in adult male and female C57BL/6J mice. The study aimed to characterise dose–response relationships, the persistence of any effect beyond metabolic clearance, and sex differences, using a continuous two-bottle choice ethanol drinking paradigm that included a short withdrawal and reintroduction phase to test durability of the effect.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (18)

Papers cited by this study that are also in Blossom

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Brown, R. T., Nicholas, C. R., Cozzi, N. V. et al. · Clinical Pharmacokinetics (2017)

A non-hallucinogenic psychedelic analogue with therapeutic potential

Cameron, L. P., Tombari, R. J., Lu, J. et al. · Nature (2020)

70 cited
Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects

Dolder, P. C., Schmid, Y., Steuer, A. E. et al. · Clinical Pharmacokinetics (2017)

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Show all 18 references
Long-term follow-up of psilocybin-facilitated smoking cessation

Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)

562 cited
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)

Psilocybin and LSD Have No Long-Lasting Effects in an Animal Model of Alcohol Relapse

Meinhardt, M. W., Güngör, C., Skorodumov, I. et al. · Neuropsychopharmacology (2020)

Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism

Barroso Flores, J., Hoffmann, R., Wagner, K. et al. · Science Advances (2021)

Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Cited By (5)

Papers in Blossom that reference this study

Psychedelic therapy and postpartum depression: priorities and prospects

Thuery, G., Crossen, F., Mc Loone, D. et al. · Therapeutic Advances in Psychopharmacology (2026)

Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT)

Witowski, C. G., Hess, M. R., Jones, N. T. et al. · European Journal of Pharmacology (2024)

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

Cameron, L. P., Benetatos, J., Lewis, V. et al. · Journal of Neuroscience (2023)

45 cited
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)

Therapeutic mechanisms of psychedelics and entactogens

Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Psilocybin sex-dependently reduces alcohol... — Research Summary & Context | Blossom